Massachusetts eHealth Collaborative

maehc.org

The Massachusetts eHealth Collaborative (MAeHC) is a pioneer and national leader in health information technology. We assist for-profit and non-profit private organizations, government agencies, and multi-stakeholder collaborative to plan, deploy, operate, and optimize health information systems. Our services range from electronic health records (EHR) implementations to health information exchange (HIE) to quality data extraction, warehousing, analytics, and reporting.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

SCIENTIST.COM ANNOUNCES THE LAUNCH OF COMPLIANCE MOBILE APP FOR IOS

Scientist.com | February 02, 2023

news image

On February 1, 2023, Scientist.com, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. Scientist.co...

Read More

Cell and Gene Therapy

SOPHIA GENETICS LAUNCHES NEW DEEP LEARNING CAPABILITIES TO SUPPORT THE DETECTION OF HOMOLOGOUS RECOMBINATION DEFICIENCIES

SOPHiA GENETICS | March 08, 2022

news image

SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. HRD is caused by a cell's impaired ability to repair ...

Read More

Medical

NUCLIXBIO ANNOUNCES A COLLABORATIVE RESEARCH AGREEMENT WITH PHARMABCINE

NuclixBio | March 15, 2022

news image

NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics. Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA™&#...

Read More

Industrial Impact

CANOPY BIOSCIENCES LAUNCHES NEXT-GENERATION CHIPCYTOMETRY™ INSTRUMENT FOR SPATIAL BIOLOGY WITH SUB-CELLULAR RESOLUTION

Canopy Biosciences | March 04, 2022

news image

Canopy Biosciences, a Bruker Company, announced the commercial launch of the CellScapeTM system, the next generation in ChipCytometryTM instrumentation, advancing the cutting-edge for quantitative in situ spatial phenotyping. ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumor microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease. The new benchtop CellScape s...

Read More
news image

Cell and Gene Therapy, Industrial Impact

SCIENTIST.COM ANNOUNCES THE LAUNCH OF COMPLIANCE MOBILE APP FOR IOS

Scientist.com | February 02, 2023

On February 1, 2023, Scientist.com, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. Scientist.co...

Read More
news image

Cell and Gene Therapy

SOPHIA GENETICS LAUNCHES NEW DEEP LEARNING CAPABILITIES TO SUPPORT THE DETECTION OF HOMOLOGOUS RECOMBINATION DEFICIENCIES

SOPHiA GENETICS | March 08, 2022

SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. HRD is caused by a cell's impaired ability to repair ...

Read More
news image

Medical

NUCLIXBIO ANNOUNCES A COLLABORATIVE RESEARCH AGREEMENT WITH PHARMABCINE

NuclixBio | March 15, 2022

NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics. Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA™&#...

Read More
news image

Industrial Impact

CANOPY BIOSCIENCES LAUNCHES NEXT-GENERATION CHIPCYTOMETRY™ INSTRUMENT FOR SPATIAL BIOLOGY WITH SUB-CELLULAR RESOLUTION

Canopy Biosciences | March 04, 2022

Canopy Biosciences, a Bruker Company, announced the commercial launch of the CellScapeTM system, the next generation in ChipCytometryTM instrumentation, advancing the cutting-edge for quantitative in situ spatial phenotyping. ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumor microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease. The new benchtop CellScape s...

Read More